Cardiogenic Shock Treatment Market driven by Increase in Cardiovascular Disorders Globally
The cardiogenic shock treatment market comprises a wide range of medications and medical devices utilized to treat low cardiac output resulting from various cardiac conditions. Drugs used in cardiogenic shock treatment include vasopressors, inotropes, PDE3 inhibitors, and dopmaines to increase blood pressure and cardiac contractility. Medical devices used include Intra-aortic Balloon Pump counterpulsation, Extracorporeal Membrane Oxygenation, and ventricular assist devices. These treatment options help stabilize the patient's hemodynamic status and buy time for definitive therapies.
The global cardiogenic shock treatment market is estimated to be valued at USD 1.10 Bn in 2024 and is expected to reach USD 1.78 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.
Key Takeaways
Key players operating in the cardiogenic shock treatment market are Abbott, Medtronic, Getinge AB, Abiomed, Terumo Corporation, Boston Scientific, F. Hoffmann-La Roche Ltd, Bayer AG, Viatris Inc., Par Pharmaceutical, AstraZeneca, Zoll Medical Corporation, Xenios AG (part of Fresenius Medical Care), Windtree Therapeutics, and Chiesi Farmaceutici S.p.A. Key players are focusing on producing innovative drugs and devices to treat cardiogenic shock and are engaging in collaborative agreements and acquisitions to strengthen their product portfolios.
The growing prevalence of
The cardiogenic shock treatment market comprises a wide range of medications and medical devices utilized to treat low cardiac output resulting from various cardiac conditions. Drugs used in cardiogenic shock treatment include vasopressors, inotropes, PDE3 inhibitors, and dopmaines to increase blood pressure and cardiac contractility. Medical devices used include Intra-aortic Balloon Pump counterpulsation, Extracorporeal Membrane Oxygenation, and ventricular assist devices. These treatment options help stabilize the patient's hemodynamic status and buy time for definitive therapies.
The global cardiogenic shock treatment market is estimated to be valued at USD 1.10 Bn in 2024 and is expected to reach USD 1.78 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.
Key Takeaways
Key players operating in the cardiogenic shock treatment market are Abbott, Medtronic, Getinge AB, Abiomed, Terumo Corporation, Boston Scientific, F. Hoffmann-La Roche Ltd, Bayer AG, Viatris Inc., Par Pharmaceutical, AstraZeneca, Zoll Medical Corporation, Xenios AG (part of Fresenius Medical Care), Windtree Therapeutics, and Chiesi Farmaceutici S.p.A. Key players are focusing on producing innovative drugs and devices to treat cardiogenic shock and are engaging in collaborative agreements and acquisitions to strengthen their product portfolios.
The growing prevalence of
07:37 AM - Nov 29, 2024 (UTC)
